Clinical Trial Detail

NCT ID NCT03873402
Title An Immunotherapy Study of Nivolumab Plus Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications

renal cell carcinoma

Therapies

Nivolumab

Ipilimumab + Nivolumab

Age Groups: senior adult

No variant requirements are available.